Recommendation 39: We recommend against statins used solely for the indication of HF in the absence of other indications for their use. Statin treatment should be in accordance with primary and secondary prevention guidelines for CVD (Strong Recommendation, High Quality Evidence).

• Routine statin therapy is unlikely to provide clinical benefit for patients with HF due to non-ischemic causes and in the absence of very high risk of vascular events (such as recent myocardial infarction, diabetes and known vascular disease).
• In those already on statin therapy, it is reasonable to consider statin withdrawal in patients with advanced HF, in polypharmacy where risks outweighs benefits or when palliative care is an overriding concern.